Perrigo completes divestiture of HRA Pharma Rare Diseases to Esteve for up to €275M

PERRIGO Co plc

Total consideration up to €275M: €190M upfront cash plus up to €85M in earnout based on sales milestones.
Proceeds to be redeployed for debt repayment; impact included in previously issued 2024 outlook.
Rare Diseases business had FY2023 net sales of ~€50M and adjusted EBITDA of ~€20M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.